期刊文献+

自体造血干细胞移植联合大剂量化疗治疗卵巢癌 被引量:1

Auto-hematopoietic stem cell transplantation with high-dose chemotherapy in treatment of ovarian cancer
下载PDF
导出
摘要 卵巢癌的治疗是妇科恶性肿瘤中较棘手的问题。70%~80%初诊卵巢癌患者已Ⅲ期和Ⅳ期,常规联合化疗有效率较高,但5年生存率很低。自体造血干细胞移植联合大剂量化疗治疗卵巢癌的结果表明,晚期卵巢癌患者以及难治性和复发的卵巢癌患者接受移植后的疗效较好且毒副作用小。 Treatment of ovarian cancer is a formidable problem in gynecologic malignant tumors. Seventy to eighty percent first diagnosed ovarian cancer is in stage Ⅲ~Ⅳ. Effective rate of conventional combined chemotherapy is high, but five-year survival rate is low. The treatment of auto-hematopoietic stem cell transplantation (AHSCT) with high-dose chemotherapy (HDC) is effective and has little side effect for the parents of advanced, refractory or recurrent ovarian cancers.
出处 《国际内科学杂志》 CAS 2007年第8期486-488,共3页 International Journal of Internal Medicine
关键词 造血干细胞移植 卵巢癌 化学疗法 Hematopoietic stem cell transplantation Ovarian neoplasms Chemotherapy
  • 相关文献

参考文献15

  • 1Bengala C, Guarneri V, Ledermann J, et al. High dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retropective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 2005,36( 1 ) :25-31.
  • 2Gratwohl A, Schmid O, Baldomero H, et al. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant, 2004,34 (10) :855-875.
  • 3Gratwohl A, Baldomero H, Demirer T, et al. Hematopoetic stem cell transplantation for solid tumors in Europe. Ann Oncol, 2004,15 (4) :653-660.
  • 4Ikeba K, Okubo M, Takeda S, et al. Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer. Int J Clin Oncol, 2004,9(2) :113-119.
  • 5Schilder R J, Gallo JM, Millenson MM, et al. Phase I trial of multiple cycles of high-dose carboplatin, pacliaxel, and topotecan with peripheral-blood stem-cell support as frontline therapy. J Clin Oncol, 2001,19(4) :1183-1194.
  • 6Bojko P, Hilger RA, Ruehm SG, et al. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone Marrow Transplant, 2003,31 (6) :487491.
  • 7Donato ML, Gershenson DM, Wharton JT, et al. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regiment for the treatment of advanced ovarian cancer. Gynecol Oncol, 2001,82 ( 3 ) : 420- 426.
  • 8Stiff PJ, Shpall EJ, Liu PY, et al. Randomized Phase Ⅱ trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol Oncol, 2004,94( 1 ) :98-106.
  • 9Morgan RJ, Doroshow JH, Leong L, et al. Phase Ⅱ trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant, 2001,28 ( 9 ) :859-863.
  • 10Barlow C, Nystrom M, Oesterling C, et al. Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer, 2004,90 (7) :1318-1322.

同被引文献12

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部